Prothena Corporation plc (PRTA)’s Financial Results Comparing With Allakos Inc. (NASDAQ:ALLK)

We are contrasting Prothena Corporation plc (NASDAQ:PRTA) and Allakos Inc. (NASDAQ:ALLK) on their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings and valuation. They both are Biotechnology companies, competing one another.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Prothena Corporation plc N/A 513.09 180.94M -4.63 0.00
Allakos Inc. N/A 0.00 36.89M -0.90 0.00

Table 1 shows gross revenue, earnings per share and valuation of the two companies.


Table 2 hightlights the net margins, return on equity and return on assets of the two companies.

Net Margins Return on Equity Return on Assets
Prothena Corporation plc 0.00% -47.9% -33%
Allakos Inc. 0.00% 0% 0%


The current Quick Ratio of Prothena Corporation plc is 19.3 while its Current Ratio is 19.3. Meanwhile, Allakos Inc. has a Current Ratio of 24.4 while its Quick Ratio is 24.4. Allakos Inc. is better positioned to pay off its short-term and long-term debts than Prothena Corporation plc.

Institutional and Insider Ownership

Roughly 0% of Prothena Corporation plc shares are owned by institutional investors while 83.3% of Allakos Inc. are owned by institutional investors. About 90.1% of Prothena Corporation plc’s share are owned by insiders.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Prothena Corporation plc -3.66% -11.14% -17.36% -17.48% -71.5% -69.14%
Allakos Inc. 6.35% 9.34% 45.87% 0% 0% 100.48%

For the past year Prothena Corporation plc has -69.14% weaker performance while Allakos Inc. has 100.48% stronger performance.


Allakos Inc. beats on 6 of the 7 factors Prothena Corporation plc.

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on the discovery, development, and commercialization of novel immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. It is developing antibody-based product candidates that include NEOD001, a monoclonal antibody that is in Phase III and Phase IIb clinical trials for the treatment of AL amyloidosis; PRX002 that has completed Phase Ib clinical trial for treating Parkinson’s disease and other related synucleinopathies; PRX003, a monoclonal antibody that is in Phase Ib for the treatment of psoriasis and other inflammatory diseases; and PRX004, a monoclonal antibody that is under preclinical development. The company has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein. Prothena Corporation plc was incorporated in 2012 and is headquartered in Dún Laoghaire, Ireland.

Allakos Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutic antibodies targeting allergic, inflammatory, and proliferative diseases. The company is developing AK002 for the treatment of eosinophilic gastritis and eosinophilic gastroenteritis, urticaria, indolent systemic mastocytosis, and severe allergic conjunctivitis. Allakos Inc. was founded in 2012 and is headquartered in San Carlos, California.